Patient Information: Summary of Product Characteristics
SPRYCEL20mg film-coated tablets
SPRYCEL50mg film-coated tablets
SPRYCEL70mg film-coated tablets
SPRYCEL80mg film-coated tablets
SPRYCEL100mg film-coated tablets
SPRYCEL140mg film-coated tablets
dasatinib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
SPRYCEL contains the active substance dasatinib. This medicine is used to treat chronic myeloid leukaemia (CML) in adults, adolescents, and children aged 1 year and above. Leukaemia is a type of cancer that affects the white blood cells. These white blood cells usually help the body fight infection. In patients with CML, a type of white blood cell called granulocytes start to multiply out of control. SPRYCEL inhibits the growth of these leukaemic cells.
SPRYCEL is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) in adults, adolescents, and children aged 1 year and above, and lymphoid blast crisis CML in adults who have not benefited from previous treatments. In patients with Ph+ ALL, a type of white blood cell called lymphocytes multiply too quickly and live too long. SPRYCEL inhibits the growth of these leukaemic cells.
If you have any questions about how SPRYCEL works or why you have been prescribed this medicine, ask your doctor.
Do not take SPRYCEL
If you think you may be allergic, consult your doctor.
Warnings and precautions
Consult your doctor or pharmacist before taking SPRYCEL
Your doctor will regularly check your condition to see if SPRYCEL is having the desired effect. You will also have regular blood tests while taking SPRYCEL.
Children and adolescents
Do not give this medicine to children under 1 year of age. Experience with the use of SPRYCEL in this age group is limited. In children taking SPRYCEL, growth and bone development should be closely monitored.
Other medicines and SPRYCEL
Tell your doctor or pharmacistif you are taking, have recently taken, or might take any other medicines.
SPRYCEL is mainly broken down in the liver. Some medicines may interfere with the effect of SPRYCEL when taken together.
The following medicines must not be used during treatment with SPRYCEL:
Do not takemedicines that neutralize stomach acid (antacidssuch as aluminium hydroxide/magnesium hydroxide) in the 2hours before or 2hours after taking SPRYCEL.
Tell your doctorif you are taking medicines to thin your bloodor prevent blood clots.
Taking SPRYCEL with food and drinks
Do not take SPRYCEL with grapefruit or grapefruit juice.
Pregnancy and breastfeeding
If you are pregnantor think you may be pregnant, tell your doctor immediately. SPRYCEL must not be used during pregnancyunless clearly necessary. Your doctor will inform you of the potential risk of taking SPRYCEL during pregnancy.
Both men and women are advised to use effective contraceptive methods during treatment with SPRYCEL.
If you are breastfeeding, tell your doctor.You must stop breastfeeding while taking SPRYCEL.
Driving and using machines
Be careful when driving or using machines if you experience side effects such as dizziness or blurred vision.
SPRYCEL contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
SPRYCEL will only be prescribed by a doctor with experience in treating leukaemia. Follow the instructions for taking this medicine exactly as your doctor has told you. If you are unsure, consult your doctor or pharmacist again. SPRYCEL is prescribed for adults and children aged 1 year and above.
The recommended starting dose for adult patients with CML in the chronic phase is 100mg once daily.
The recommended starting dose for adult patients with CML in the accelerated phase or blast crisis or Ph+ ALL is 140mg once daily.
Dosing regimen in children with CML in the chronic phase or Ph+ ALL based on body weightSPRYCEL is given orally once daily, either as tablets or as a powder for oral suspension. SPRYCEL tablets are not recommended in patients who weigh less than 10 kg. The powder for oral suspension should be used in patients who weigh less than 10 kg and in patients who cannot swallow tablets. A dose change may be required when switching between formulations (i.e., tablets and powder for oral suspension), so do not switch between formulations.
Your doctor will decide on the correct formulation and dose based on your weight, side effects, and response to treatment. In children, the starting dose of SPRYCEL is calculated according to body weight as shown below:
Body weight (kg)a | Daily dose (mg) |
10 to less than 20 kg | 40 mg |
20 to less than 30 kg | 60 mg |
30 to less than 45 kg | 70 mg |
45 kg or more | 100 mg |
a SPRYCEL tablets are not recommended in patients who weigh less than 10 kg; the powder for oral suspension should be used in these patients.
There is no recommended dose for SPRYCEL in children under 1 year of age.
Depending on how you respond to treatment, your doctor may prescribe a higher or lower dose, or even interrupt treatment briefly. To take higher or lower doses, you may need to take combinations of tablets of different strengths.
SPRYCEL tablets may be presented in calendar blister packs.These are blisters that show the days of the week. The arrows indicate the next tablet to be taken according to your treatment schedule.
How to take SPRYCEL
Take the tablets at the same time each day.Swallow the tablets whole. Do not crush, cut, or chew them. Do not take the tablets dissolved. You cannot be sure you are getting the correct dose if you crush, cut, chew, or dissolve the tablets. SPRYCEL tablets can be taken with or without food.
Special handling instructions for SPRYCEL
It is unlikely that SPRYCEL tablets will break, but if they do, people other than the patient should wear gloves when handling SPRYCEL.
How long to take SPRYCEL
Take SPRYCEL daily until your doctor tells you to stop. Make sure you take SPRYCEL for the duration your doctor has prescribed.
If you take more SPRYCEL than you should
If you accidentally take too many tablets, contact your doctor immediately. You may need medical attention.
If you forget to take SPRYCEL
Do not take a double dose to make up for forgotten doses. Take the next dose at the usual time.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
The following may be signs of serious adverse effects:
Contact your doctor immediatelyif you notice any of the above.
Very common adverse effects (may affect more than 1 in 10 patients)
Common adverse effects (may affect up to 1 in 10 patients)
Uncommon adverse effects (may affect up to 1 in 100 patients)
Rare adverse effects (may affect up to 1 in 1000 patients)
Other adverse effects that have been reported with unknown frequency (cannot be estimated from available data)
Your doctor will check if you have any of these effects during your treatment.
Reporting adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the label of the bottle after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be thrown away through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This will help protect the environment.
Composition of SPRYCEL
Appearance of the product and package contents
SPRYCEL 20 mg: the film-coated tablets are white to off-white, biconvex, round, with "BMS" engraved on one side and "527" on the other.
SPRYCEL 50 mg: the film-coated tablets are white to off-white, biconvex, oval, with "BMS" engraved on one side and "528" on the other.
SPRYCEL 70 mg: the film-coated tablets are white to off-white, biconvex, round, with "BMS" engraved on one side and "524" on the other.
SPRYCEL 80 mg: the film-coated tablets are white to off-white, biconvex, triangular, with "BMS 80" engraved on one side and "855" on the other.
SPRYCEL 100 mg: the film-coated tablets are white to off-white, biconvex, oval, with "BMS 100" engraved on one side and "852" on the other.
SPRYCEL 140 mg: the film-coated tablets are white to off-white, biconvex, round, with "BMS 140" engraved on one side and "857" on the other.
SPRYCEL 20 mg, 50 mg, or 70 mg film-coated tablets are available in packages containing 56 film-coated tablets in 4 calendar blister packs of 14 film-coated tablets each, and in packages with 60 x 1 film-coated tablets in precut unit-dose blisters. They are also available in child-resistant closure bottles with 60 film-coated tablets. Each box contains one bottle.
SPRYCEL 80 mg, 100 mg, or 140 mg film-coated tablets are available in packages containing 30 x 1 film-coated tablets in precut unit-dose blisters. They are also available in child-resistant closure bottles with 30 film-coated tablets. Each box contains one bottle.
Not all pack sizes may be marketed.
Marketing authorization holder
Bristol-Myers Squibb Pharma EEIG Plaza 254 Blanchardstown Corporate Park 2
Dublin 15, D15 T867 Ireland
Manufacturer
Swords Laboratories Unlimited Company T/A Bristol-Myers Squibb Pharmaceutical Operations, External Manufacturing
Plaza 254
Blanchardstown Corporate Park 2
Dublin 15, D15 T867
Ireland
CATALENT ANAGNI S.R.L.
Loc. Fontana del Ceraso snc
Strada Provinciale 12 Casilina, 41
03012 Anagni (FR) Italy
Date of the last revision of this prospectus:
Detailed information about this medicine is available on the European Medicines Agency website:
http://www.emea.europa.eu. There are also links to other websites about rare diseases and orphan medicines.